Sildenafil bioavailability is a pharmacokinetic measure of the fraction of an administered dose that reaches the systemic circulation as unchanged drug. Current sildenafil labeling reports a mean absolute oral bioavailability of approximately 41%, with a reported range of 25% to 63%.
That percentage is related to absorption but is not simply a measurement of how much sildenafil crosses the gastrointestinal wall. Oral systemic availability reflects the combined result of gastrointestinal absorption and presystemic processes occurring before unchanged sildenafil reaches the general circulation.
This page focuses on the meaning, measurement and interpretation of sildenafil bioavailability, including what the reported 41% value represents and what it does not. The mechanics of gastrointestinal uptake are covered on the sildenafil absorption page, while total concentration-time exposure is treated separately on the sildenafil AUC page.
Bioavailability describes the fraction of an administered dose that reaches systemic circulation as unchanged drug. For oral sildenafil, prescribing information reports a mean absolute bioavailability of about 41%, with values ranging from 25% to 63% in the underlying pharmacokinetic characterization.
The value should be interpreted as systemic availability relative to an intravenous reference, not as the percentage of the oral dose that simply dissolves or crosses the intestinal membrane. Drug can be absorbed from the gastrointestinal tract yet undergo presystemic processing before unchanged sildenafil reaches systemic plasma.
Within the broader sildenafil pharmacokinetic framework, bioavailability connects oral drug input with the concentration-time profile that appears after systemic entry. It is therefore an extent-of-availability concept rather than a direct measure of absorption speed, peak concentration or pharmacological response.
| Concept | Primary Question | What It Describes |
|---|---|---|
| Administered dose | How much drug is given? | Input before absorption and presystemic processing. |
| Absorption | How does drug move from the administration site toward circulation? | Pre-systemic uptake process. |
| Bioavailability | What fraction reaches systemic circulation unchanged? | Mean absolute oral sildenafil bioavailability is approximately 41% in labeling. |
| Exposure | How much circulating drug exposure occurs over time? | Concentration-time behavior after systemic entry. |
Absolute bioavailability compares systemic exposure after a non-intravenous route with exposure after intravenous administration. The intravenous route provides the reference because drug administered directly into systemic circulation is considered completely systemically available for the purpose of the comparison.
For sildenafil, labeling reports a mean absolute oral bioavailability of approximately 41% and a range of 25% to 63%. In practical PK terms, this means dose-normalized oral exposure is substantially lower than the exposure expected if the same systemic dose were introduced directly through an intravenous reference route.
The 41% value should not be interpreted to mean that exactly 59% of an oral sildenafil dose failed to be absorbed. Absolute bioavailability reflects the net result of absorption plus presystemic loss, and the reported value does not by itself quantify how much of the difference is attributable to incomplete gastrointestinal uptake versus presystemic metabolism.
| Route | Pre-Systemic Steps | Role in Bioavailability Assessment |
|---|---|---|
| Oral | Requires gastrointestinal absorption and is subject to presystemic processing | Test route whose systemic availability is being characterized. |
| Intravenous | Bypasses gastrointestinal absorption and presystemic entry loss | Reference representing complete systemic input. |
| Sildenafil oral bioavailability | Net result after oral absorption and presystemic processing | Mean absolute bioavailability approximately 41% in labeling. |
Bioavailability is not determined from a single plasma concentration. Pharmacokinetic studies collect serial sildenafil concentrations after administration and calculate the area under the resulting concentration-time curve so that total systemic exposure can be compared across routes.
For absolute bioavailability, oral and intravenous exposure are normalized for the doses administered. Conceptually, absolute bioavailability can be expressed as the dose-normalized oral AUC divided by the dose-normalized intravenous AUC. Dose normalization is necessary when the oral and intravenous comparison doses are not identical.
AUC is therefore a measurement used in the calculation rather than a synonym for bioavailability itself. AUC describes integrated systemic exposure; absolute bioavailability uses comparative dose-normalized exposure to estimate what fraction of the non-intravenous dose became systemically available. The sildenafil AUC guide examines that exposure metric in its own right.
| Measurement Element | Role |
|---|---|
| Serial plasma samples | Provide sildenafil concentration measurements across time. |
| Concentration-time profile | Shows how systemic concentrations evolve after administration. |
| AUC | Summarizes systemic exposure for route comparison. |
| Dose normalization | Allows oral and intravenous exposure to be compared appropriately. |
| Intravenous reference | Provides the benchmark representing complete systemic availability. |
Absorption describes the movement of sildenafil from the gastrointestinal environment across biological barriers toward the circulation. Bioavailability asks a later and more specific question: what fraction of the administered dose ultimately reaches systemic circulation as unchanged sildenafil?
The distinction is important when interpreting the reported mean absolute bioavailability of 41%. That number should not be read as meaning that only 41% of sildenafil crosses the gastrointestinal barrier. Some drug can be absorbed and then metabolized before unchanged parent sildenafil reaches the systemic circulation.
Absorption can also be described in terms of rate, whereas absolute bioavailability primarily describes the extent of systemic availability. The upstream mechanics of dissolution, gastrointestinal transit and intestinal uptake are covered in greater detail on the sildenafil absorption guide.
| Feature | Absorption | Bioavailability |
|---|---|---|
| Primary focus | Movement from administration site toward circulation | Fraction reaching systemic circulation unchanged |
| Main domain | Gastrointestinal and membrane uptake | Net result after absorption and presystemic processing |
| Rate-sensitive? | Yes, absorption can be discussed in terms of rate | Primarily describes extent of systemic availability |
| Does 41% mean 41% was absorbed? | No; absorption and systemic availability are different | 41% is the reported mean absolute systemic bioavailability |
After gastrointestinal uptake, orally administered sildenafil does not move directly from the intestinal lumen into the general systemic circulation without intermediate processing. Drug reaching the portal and presystemic pathway can undergo metabolism before unchanged parent sildenafil appears in systemic plasma.
This is one reason oral systemic availability can be lower than the amount initially absorbed. Sildenafil is metabolized predominantly through CYP3A pathways, with CYP2C9 playing a smaller role, although bioavailability data alone do not quantify exactly how much of the reduction in systemic availability occurs at each presystemic site or step.
The key point for interpreting bioavailability is therefore the distinction between uptake and survival to systemic circulation as unchanged parent drug. The metabolic pathways themselves belong to the sildenafil metabolism guide; their role here is limited to explaining why absorption and absolute bioavailability are not interchangeable.
| Stage | Conceptual Outcome |
|---|---|
| Oral administration | Full administered dose enters the gastrointestinal pathway. |
| Gastrointestinal uptake | A fraction crosses the intestinal barrier. |
| Presystemic processing | Some absorbed drug can be metabolized before general circulation. |
| Systemic circulation | Unchanged sildenafil that survives these processes contributes to absolute bioavailability. |
Bioavailability and AUC are closely related but answer different pharmacokinetic questions. Bioavailability describes the fraction of an administered dose that becomes systemically available as unchanged drug, whereas AUC describes integrated plasma concentration across time.
Absolute bioavailability is calculated using comparative dose-normalized AUC data, but an AUC value from a single route is not itself a bioavailability percentage. AUC is influenced by the amount of drug entering systemic circulation as well as the rate at which circulating sildenafil is subsequently cleared.
This distinction becomes important whenever systemic exposure changes. A higher AUC can reflect greater systemic input, reduced clearance or both, so an exposure difference cannot automatically be attributed to altered bioavailability. The sildenafil exposure guide places AUC alongside other measures of systemic exposure, while the dedicated AUC page addresses its calculation and interpretation.
| Measure | Meaning | Typical Interpretation |
|---|---|---|
| Bioavailability | Fraction of dose reaching systemic circulation unchanged | Systemic availability |
| AUC | Integrated plasma concentration over time | Total systemic exposure over the measured interval |
| Cmax | Maximum observed plasma concentration | Peak concentration |
| Tmax | Time of maximum observed concentration | Peak timing |
Cmax and Tmax describe features of the observed concentration-time profile rather than the absolute fraction of an administered dose reaching systemic circulation. Cmax represents the observed concentration peak, while Tmax identifies when that peak occurs.
This difference is particularly important for sildenafil because changes in absorption rate can substantially alter peak-related parameters without implying an equivalent change in absolute bioavailability. A concentration profile can become later and flatter while still producing systemic exposure across the remainder of the curve.
Peak magnitude and timing are therefore complementary PK measurements rather than substitutes for bioavailability. They are examined separately on the sildenafil Cmax and sildenafil Tmax pages.
Absolute bioavailability uses an intravenous reference to estimate what fraction of a non-intravenous dose reaches systemic circulation. Relative bioavailability instead compares systemic exposure between two non-intravenous formulations or products, so no intravenous reference is required.
Sildenafil labeling provides a practical formulation-comparison example: bioequivalence was established between a 20 mg tablet and a 10 mg/mL oral suspension when each provided a 20 mg single dose of sildenafil as citrate. That finding compares formulation exposure rather than recalculating the drug's absolute 41% oral bioavailability.
Relative bioavailability and formal bioequivalence are related comparison concepts but should not be collapsed into a single term. Bioequivalence uses predefined pharmacokinetic and statistical criteria when comparing products. Those regulatory principles are addressed separately on the sildenafil bioequivalence page.
| Concept | Reference | Primary Question |
|---|---|---|
| Absolute bioavailability | Intravenous administration | What fraction of the dose becomes systemically available? |
| Relative bioavailability | Another non-IV product or formulation | How does systemic exposure compare between formulations? |
| Bioequivalence | Reference product under defined study conditions | Are key exposure measures sufficiently similar under regulatory criteria? |
Sildenafil labeling reports mean absolute oral bioavailability of approximately 41% with a range of 25% to 63%. The range is an important reminder that a population mean is not a fixed percentage that should be assumed for every individual exposure.
Variation in oral systemic availability can reflect differences in gastrointestinal conditions and presystemic processing. At the same time, variation in measured AUC does not automatically mean that bioavailability itself changed, because systemic clearance also determines the concentration-time exposure observed after drug reaches the circulation.
Study design and analytical methods also influence how pharmacokinetic parameters are estimated. For that reason, variability in bioavailability should be separated from variability in Cmax, Tmax, AUC or clearance rather than treating all exposure differences as one phenomenon. The broader framework is covered on the sildenafil PK variability page.
| Source | Potential Relationship to Observed PK |
|---|---|
| GI absorption conditions | Can alter the rate or extent of drug uptake. |
| Presystemic metabolism | Can change the fraction reaching systemic circulation unchanged. |
| Systemic clearance | Can alter AUC without necessarily changing absolute bioavailability. |
| Study design and sampling | Can influence precision of estimated PK parameters. |
Food is a useful example of why absorption rate, peak concentration and bioavailability need to remain separate concepts. For conventional sildenafil tablets, labeling reports that a high-fat meal delays mean Tmax by about 60 minutes and reduces mean Cmax by about 29%, demonstrating a clear change in the rate and early shape of systemic appearance.
Those peak-related changes should not automatically be converted into the same percentage change in absolute bioavailability. Tmax describes peak timing and Cmax describes peak magnitude, while bioavailability concerns the extent of unchanged sildenafil reaching systemic circulation relative to the administered dose.
Different sildenafil formulations can also have formulation-specific food-effect findings, so quantitative interpretation belongs on the sildenafil food-effects guide. The purpose of the example here is to show why slower absorption is not synonymous with proportionally lower systemic bioavailability.
Bioavailability is a pharmacokinetic measurement, not a direct measure of pharmacological or clinical response. The reported mean absolute bioavailability of 41% describes systemic availability of unchanged sildenafil after oral administration; it does not mean that the drug produces 41% of a hypothetical maximum clinical effect.
Once sildenafil reaches the systemic circulation, pharmacological response depends on additional processes including distribution, target interaction, concentration-effect relationships, active-metabolite contribution and individual biological context. Differences in systemic availability can affect exposure without creating a simple one-to-one relationship with clinical outcome.
A higher or lower bioavailability value should therefore not be translated directly into a proportional statement about effectiveness, onset or duration. The exposure-effect side of the research framework belongs to sildenafil pharmacodynamics, while the general mechanism is explained separately on how sildenafil works.
| Domain | What It Measures |
|---|---|
| Bioavailability | Fraction of administered drug reaching systemic circulation unchanged. |
| Systemic exposure | Plasma drug concentration integrated across time. |
| Pharmacodynamics | Biological effects associated with drug exposure. |
| Clinical response | Observed outcome influenced by exposure and additional biological factors. |
Sildenafil labeling reports a mean absolute oral bioavailability of approximately 41%, with a range of 25% to 63%. Bioavailability describes the fraction of an administered dose reaching systemic circulation as unchanged drug.
Absolute bioavailability compares dose-normalized systemic exposure after a non-intravenous route with dose-normalized exposure after intravenous administration, which serves as the reference for complete systemic availability.
No. Absorption and absolute bioavailability are different concepts. Drug can cross the gastrointestinal barrier and still undergo presystemic metabolism before unchanged sildenafil reaches the systemic circulation.
No. Bioavailability describes systemic availability as a fraction of the administered dose, while AUC measures integrated plasma exposure across time. Dose-normalized AUC comparisons are used when estimating absolute bioavailability.
Not directly. Cmax describes peak plasma concentration and Tmax describes the time of that peak. Both can reflect absorption behavior, but neither is the same as the extent of systemic availability.
Not necessarily. Bioavailability is a pharmacokinetic measure of systemic drug availability, while clinical response depends on pharmacodynamic, exposure and individual biological factors.